Nbsp17 July 2012 Bangalore India Today More And More Countries Across The Globe Are Dedicated Towards Developing A Favourable Environment For The Growth Of Biopharmaceutical And Biosimilar Products In Their Respective Markets The Indian Regulatory Bodies Like The Dcgi And The Icmr Too Are Constantly Revising Their Norms And Standards To Promote Clinical Trials And Eventually The Growth Of Biotech Products In The Country This Is Largely Due To The Fact That These Bioproducts Are Solutions To Some Of The Most Dreaded Diseases And Require High Manufacturing And Marketing Investmentswith These Developments In The Background Cphi Conferences Is Launching Global Bioclinical Trials 2012 A Highly Anticipated Strategic 4day Initiative 2528 September Bangalore India Focused On The Challenges Pertaining To Conduct Of Clinical Trials For The Approval Of Sensitive Biopharmaceuticals And Biosimilars Drugs An Interactive Seminar On Lsquoemerging Market Regulations Brazil China Russia Latam Amp Malaysiarsquo Will Take Place On 25 September And An Exclusive Workshop On Pharmacokineticspharmacodynamics Studies On 28 Septemberthe 2day Conference 2627 September Will Provide Solutions To Dealing With The Current Regulatory Challenges And Guidelines For Robust Design Of Clinical Trials Economic Patient Recruitment And Retention Protocols Latest Tool And Techniques For Clinical Data Management And Medical Writing Along With Updates On The Latest Pharmacovigilance Trendseminent Speakers Like Dr Ragunadarao Digumarti Hod Oncology Nizams Hyderabad Mr Solomon Yimam Assistant Director Clinical Research Us Fda Mr Scott Laufenberg Assistant Directorbimo Us Fda Dr Arani Chatterjee Vp Clinical Research Panacea Biotec Dr Yk Gupta National Scientific Coordinator Pharmacovigilance Programme Of Indianbsp Dr Sanjeev Hegde Gm Clinical Development Piramal Healthcare Dr Goutam Pujari Vp Clinical Research Operations Glenmark Pharmaceuticals Dr Deven Parmar Ceo Amp Medical Director Karmic Life Sciences Dr Ajay Gautam Executive Director And Head Of Emerging Markets Astranezeneca China Dr Sanish Davis Director Clinical Pharmacology In Emerging Markets Msd Mr Arjun Roy Head Cdm Amp Biometrics Ranbaxy Among Other Industry Experts Are Already On Board Providing The Latest Updates For Development Of Biopharmaceuticals And Biosimilars In Their Respective Organisationsglobal Bioclinical Trials 2012 Will Bring Together 100 Regulators Heads Of Clinical Research Clinical Operations Amp Clinical Rampd Pharmacovigilance Medical Affairs Clinical Aata Management And Medical Doctors From Across Biopharmaceutical And Biosimilars Companies Across India And The World To Help Increase Awareness About The Latest Developments Pertaining To Clinical Trials Of Bioproducts For More Details You Can Log On To Wwwbioclinicaltrialscomofferfor Further Information Please Contactnbspms Asan Banocustomer Services Executivecphi Conferences91 022 4046 1466conferencesindiaubmcom Nbspcphi India Is A Ubm Brand And Is The Largest And Most Important Meeting Place For The Indian Pharma Industry Each Year Cphi Attracts Around 850 Exhibitors And 30000 Visitors To The Show Providing Us With An Unrivalled Reach To All The Key Decision Makers In The Indian Pharma Industry Nbspubm India Is A Subsidiary Of Ubm Plc Which Is The Second Largest Independent Exhibition Organiser In The World It Is The Largest Trade Exhibition Organiser In India Responsible For 26 Exhibitions In Different Locations Across The Country The Company Is Also Involved In The Organisation Of Conference Programmes Throughout India And In The Publications Of Trade Journals And Magazines For Further Details Please Visit Httpwwwubmindiainnbsp
